

Serial No.: 08/702,114

- 2 -

Assistant Commissioner for Patents

1. (Twice Amended) A chimeric fatty body[-pro-]GRF analog with increased biological potency, of the following general formula:

A1-A2-Asp-Ala-Ile-Phe-Thr-A8-Ser-Tyr-Arg-Lys-Val-Leu-
A15-Gln-Leu-A18-Ala-Arg-Lys-Leu-Leu-A24-Asp-Ile-A27-
A28-Arg-A30-R₀

wherein,

A1 is Tyr or His;

A2 is Val or Ala;

A8 is Asn or Ser;

A18 is Ser or Thr ✓

A15 is Ala or Gly;

A24 is Gln or His;


A27 is Met, Ile or Nle;

A28 is Ser or Asp;

A30 is any amino acid sequence of 1 to 15 residues;

R₀ is NH₂;

wherein A1 is N- [or O-]anchored by a hydrophobic tail of the following general formula I:



wherein,

G is a carbonyl, a phosphonyl, a sulfonyl or a sulfinyl group;

X is a oxygen atom, sulfur atom or an amino group (NH);

(W=Y) represents *cis* or *trans* (CH=CR₅);

(W'=Y') represents *cis* or *trans* (CH=CR₆);

Z is an oxygen or a sulfur atom;

R₁, R₂ and R₃, independently, are selected from [a hydroxyl group,] a hydrogen atom, and a linear or branched C₁-C₆ alkyl group;

R₄ is [an hydroxyl group,] a hydrogen atom [or a linear or branched C₅-C₉ alkyl group];

41-

Serial No.: 08/702,114

- 3 -

Assistant Commissioner for Patents

Cont'd.

R_5 and R_6 , independently, are a hydrogen atom or a linear or branched C_1 - C_4 alkyl group;

a is [0 or] 1;

b is 0 [or 1];

c is 0 to [8]3;

d is 0 or 1;

e is 0 to [8]3;

f is 0 or 1;

g is 0 to [8]4;

h is 0 [to 1];

wherein the sum of d + f = 1 or 2 and the sum of a, b, c, d, e, f, g and h is such that the hydrophobic tail of formula I has a linear main chain of between 5 and 7 carbon atoms [(C, O and/or S)].

12
8. The chimeric fatty body[-pro-]GRF analog of claim [4]1, wherein c is 0.

13
8. The chimeric fatty body[-pro-]GRF analog of claim 5, wherein A30 is Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu.

14
8. The chimeric fatty body[-pro-]GRF analog of claim 6, wherein R_0 is NH_2 .

15
8. The chimeric fatty body[-pro-]GRE analog of claim 1, of the formula $cisCH_3-CH_2-CH=CH-CH_2-CO-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH_2$ or $transCH_3-CH_2-CH=CH-CH_2-CO-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH_2$.

42

Serial No.: 08/702,114

- 4 -

Assistant Commissioner for Patents

9. The chimeric fatty body[-pro-]GRF analog of claim 1, wherein [A1 is Tyr or His N-alpha anchored by hydrophobic tail of formula I, wherein a= 1; each of b and h= 0;] the sum d + f = 2; [G= carbonyl;] R₁, R₂, R₃ and R₄= hydrogen atom and the sum c + e + g= 2, 3 or 4.

10. The chimeric fatty body[-pro-]GRF analog of claim 1, wherein [A1 is Tyr or His N-alpha anchored by hydrophobic tail of formula I, wherein a= 1; each of b and h= 0; the sum of d + f = 1 or 2; G= carbonyl;] R₁, R₂, R₃ and R₄= hydrogen atom; and the sum c + e + g= 3, 4 or 5.

11. A pharmaceutical formulation for inducing growth hormone release which comprises as an active ingredient a GRF analog as claimed in claim 1 or 21.8 in association with a pharmaceutically acceptable carrier, excipient or diluent.

12. A method of increasing the level of growth hormone in a patient which comprises administering to said patient an effective amount of a GRF analog as claimed in claim 1 or 21.8

13. A method for the diagnosis of growth hormone deficiencies in patients, which comprises administering to said patient a GRF analog as claimed in claim 1 or 21.8 and measuring the growth hormone response.

14. A method for the treatment of pituitary dwarfism or growth retardation in a patient, which comprises administering to said patient an effective amount of a GRF analog as claimed in claim 1 or 21.8

15. A method for the treatment of wound or bone healing in a patient, which comprises administering to said patient an effective amount of a GRF analog as claimed in claim 1 or 21.8

43

Serial No.: 08/702,114

- 5 -

Assistant Commissioner for Patents

14
16. A method for the treatment of osteoporosis in a patient, which comprises administering to said patient an effective amount of a GRF analog as claimed in claim 1 or 21. 8

15
17. A method for improving protein anabolism in human or animal, which comprises administering to said human or animal an effective amount of a GRF analog as claimed in claim 1 or

16
18. A method for inducing a lipolytic effect in human or animal inflicted with clinical obesity, which comprises administering to said human or animal an effective amount of a GRF analog as claimed in claim 1 or 21. 8

17
19. A method for the overall upgrading of somatroph function in human or animal, which comprises administering to said human or animal an effective amount of a GRF analog as claimed in claim 1 or 21. 8

Please add claim 21:

21. (Added) The chimeric fatty body GRF analog of claim 1. 4
of the formula $\text{transCH}_3\text{-CH}_2\text{-CH=CH-CH}_2\text{-CO-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH}_2$.

Please cancel claims 2, 3, 4 and 20.

44